Renzapride
Renzapride Basic information
- Product Name:
- Renzapride
- Synonyms:
-
- Renzapride
- 4-amino-N-[(4R,5S)-1-azabicyclo[3.3.1]nonan-4-yl]-5-chloro-2-methoxybenzamide
- Benzamide, 4-amino-N-(1R,4S,5R)-1-azabicyclo[3.3.1]non-4-yl-5-chloro-2-methoxy-, rel-
- Renzapridum
- BRL-24924A
- program AZM-112
- CAS:
- 112727-80-7
- MF:
- C16H22ClN3O2
- MW:
- 323.82
- Product Categories:
-
- API
- Mol File:
- 112727-80-7.mol
Renzapride Chemical Properties
- Melting point:
- >260°
- Boiling point:
- 469.2±45.0 °C(Predicted)
- Density
- 1.30±0.1 g/cm3(Predicted)
- storage temp.
- Store at -20°C
- pka
- 13.59±0.20(Predicted)
- form
- Solid
- color
- White to off-white
Renzapride Usage And Synthesis
Uses
Renzapride (BRL 24924), a substituted benzamide, is a full 5-HT4 receptor agonist with a Ki value of 115 nM. Renzapride (BRL 24924) is also a 5HT2b and 5HT3 receptor antagonist[1]. Renzapride could be used for constipation predominant irritable bowel syndrome (C-IBS) study[2].
in vivo
Renzapride (BRL 24924) (100 μg i.v.) results in a partial reverse of both the delayed solid and liquid meals emptying[2].
Renzapride (BRL 24924) (0.5-1 mg/kg) significantly increases the rate of emptying of a 51Cr-labeled liquid meal from the murine stomach[4].
| Animal Model: | Dog (simulating gastroparesis)[2] |
| Dosage: | 100 μg/kg |
| Administration: | i.v. |
| Result: | Results in a partial reverse of both the delayed solid and liquid meals emptying. |
| Animal Model: | Mice (30-45g)[2] |
| Dosage: | 0.5-1 mg/kg |
| Administration: | p.o. |
| Result: | Significantly increase the rate of emptying of a 51Cr-labeled liquid meal from the murine stomach. |
IC 50
5-HT4 Receptor: 115 nM (Ki)
References
[1] Camilleri M, et al. Effect of renzapride on transit in constipation-predominant irritable bowel syndrome. Clin Gastroenterol Hepatol. 2004;2(10):895-904. DOI:10.1016/s1542-3565(04)00391-x
[2] Scarpellini E, et al. Renzapride: a new drug for the treatment of constipation in the irritable bowel syndrome. Expert Opin Investig Drugs. 2008;17(11):1663-1670. DOI:10.1517/13543784.17.11.1663
[3] Nagakura Y, et al. Pharmacological properties of a novel gastrointestinal prokinetic benzamide selective for human 5-HT4 receptor versus human 5-HT3 receptor. Pharmacol Res. 1999;39(5):375-382. DOI:10.1006/phrs.1998.0454
[4] Mawe GM, et al. Blockade of 5-HT-mediated enteric slow EPSPs by BRL 24924: gastrokinetic effects. Am J Physiol. 1989;257(3 Pt 1):G386-G396. DOI:10.1152/ajpgi.1989.257.3.G386
RenzaprideSupplier
- Tel
- +86 21 61551611
- Tel
- +1-631-485-4226
- inquiry@bocsci.com
- Tel
- 4008200310
- marketing@tsbiochem.com
- Tel
- 021-65675885 18964387627
- customer_service@efebio.com
- Tel
- 025-025-66113011 18626450290
- cb5@aikonchem.com